Abstract
Objectives:
A systematic characterization of the long-term sequelae after the severest form of COVID-19 requiring ECMO-therapy is lacking. Here, we present 2-year follow-up data of COVID-19 ECMO survivors, and analyze the cardiopulmonary, neurocognitive, psychological, and functional status, plus health-related quality of life (HRQL).
Methods:
From 04/2020 to 09/2021, 60 COVID patients were supported with ECMO. Survival to discharge was 40.0% (n = 24), and 6-month survival was 33.3% (n = 20). Follow-ups were performed via phone and mail using validated tools. Six-month outcomes have been published before.
Results:
At 2 years, 20 patients were alive. N = 19 agreed to participate in this study (median age 57.0 (45.0–63.0) years, 21.1% female). The cardiopulmonary status was satisfactory (78.9% in NYHA level I-II). Altogether, 84.2% were vastly independent in daily life. However, 47.4% still showed cognitive impairment, 21.1% moderate, 15.8% severe depression, and 15.8% posttraumatic stress disorder symptoms. HRQL subscale results were similar to 6 months, but patients self-rated their overall health significantly better (70.0% (50.0%–80.0%) vs 50.0% (30.0%–80.0%), p = 0.04). The number of patients working was increasing. Social life remained markedly affected.
Conclusions:
Two-year outcomes in COVID-19 ECMO patients were stable to improving as compared to 6-month results. However, long-term impairments affected all aspects of life. Long COVID specifically, and post ECMO sequelae in general need to be characterized further to enable maximum recovery.
Get full access to this article
View all access options for this article.